Cancer | Tokio X'press - Part 10

💊Opdivo (nivolumab) Demonstrates Superior Three-Year Survival Benefit for Patients with Previously Treated Advanced Renal Cell Carcinoma (RCC)

Tuesday November 7th, 2017By Tokio X'press Cancer, FDA Opdivo

Two important clinical trials of Ono Pharmaceuticals, Opivo® (generic name: niborumab) demonstrate the benefits of three-year survival in patients 20170911

Two important clinical trials

Tuesday September 12th, 2017By Tokio X'press Cancer, JPN ONO

Two important clinical trials

A ‘pen’ that can diagnose cancer in 10 seconds 2017/09/10

A ‘pen’ that can d

Monday September 11th, 2017By Tokio X'press Cancer, USA University of Texas

A ‘pen’ that can d